The Consortium BAYCELLator comprises eight scientific projects, with four focusing on higher-level enabler technologies: viral vectors and systems (Project 1), universal donor cells (Projects 2 and 6), and process automation (Project 3). These projects are designed to yield benefits not only for the BAYCELLator projects in later development phases but also for future projects within Bavaria. The aim is to expedite the development and testing of future approaches by leveraging the knowledge gained from these endeavors.

Furthermore, all projects within the consortium are dedicated to addressing significant medical challenges, striving to pioneer innovative treatments for refractory cancer patients. In this context, Projects 1, 2, 6, and 7 focus on various hematological conditions, while Projects 3, 4, 5, and 8 center on solid tumor diseases.